Episode
How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad
- Podcast
- Cell & Gene: The Podcast
- Published
- Jul 16, 2026
- Duration seconds
- 1083
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/how-precision-oncology-is-redefining-cancer-drug-development-with-aprea-therapeutics-dr-oren-gilad/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/how-precision-oncology-is-redefining-cancer-drug-development-with-aprea-therapeutics-dr-oren-gilad.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision ...